TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02689141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
Study: NCT02738294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ME-NBI observation and ME-NBI targeted biopsy
Description: The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
Study: NCT02304133

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study: NCT03063918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive a workbook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive personalized dietary intervention
Study: NCT02204306

Intervention type: GENETIC
Group type: OTHER
Intervention: TSER
Description: TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.

Intervention type: GENETIC
Group type: OTHER
Intervention: TSER
Description: TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.

Intervention type: GENETIC
Group type: OTHER
Intervention: TSER
Description: TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
Study: NCT04326621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Release Technique (PRT)
Description: A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release Technique (PRT)
Description: A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
Study: NCT00656994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
Study: NCT04326621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: exercises
Study: NCT02783651

Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care

Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care
Study: NCT02052154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prime-boost pneumococcal immunization
Description: 2 months between the 2 vaccines
Study: NCT01293214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb transplantation
Study: NCT04326621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: exercises
Study: NCT02771535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-MCT
Description: Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Training
Description: Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
Study: NCT04676659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK-tPA
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK-tPA
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK-tPA
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNK-tPA
Description: Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
Study: NCT03630107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 5101 Shampoo for Scalp and Hair
Description: Wash the hair at least three times a week for a period of four weeks
Study: NCT03851224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: immediate implant with immediate loading using no graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: study group
Description: immediate implant with immediate loading using autogenous bone graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: study group 2
Description: immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
Study: NCT01998906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
Study: NCT01039324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reports
Description: Primary care event reports and patient letters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reports and Notices
Description: Primary care event reports, patient letters and care manager notices
Study: NCT01998906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV on Day 1 of Cycles 1 through 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMF
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF
Description: CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Study: NCT01039324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: This is the study's control group
Study: NCT01463696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8242
Description: 10 mg, 100 mg and 150 mg capsules
Study: NCT04597645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic elastic band resistance training
Description: A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
Study: NCT00971581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC KETOPROFEN+OMEPRAZOLE
Description: Ketoprofen + Omeprazole FDC once daily for 4 weeks
Study: NCT06334159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane
Description: Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane
Description: Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
Study: NCT03018197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Education
Description: Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
Study: NCT02508584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-mycoplasma hominis antibodies
Description: provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
Study: NCT01562392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: berries and vegetables
Description: Daily (5 w) supplementation with specific vegetables and berries

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control product
Description: Supplementation (daily,5 w) with a control product without berries and vegetables.
Study: NCT04027283

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol
Description: 50g erythritol dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol + lactisole
Description: 50g erythritol + lactisole (450ppm) dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose
Description: 25g D-allulose dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose + lactisole
Description: 25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water + lactisole
Description: 300mL tap water + lactisole (450ppm)
Study: NCT02355652

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical total knee replacement using cemented components
Description: Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical total knee replacement using uncemented components
Description: Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
Study: NCT01960712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transpapillary plastic stent (7-10 Fr)
Description: Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
Study: NCT03167463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flap
Description: Repair choanal atresia with using flap during surgery
Study: NCT04067453

Intervention type: OTHER
Intervention: Fatiguing contractions
Description: 10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
Study: NCT04026386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center Based or In Home Early Intervention Program
Description: This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
Study: NCT04547842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine 30 MG
Description: mirtazapine is given in arm M to prevent PONV
Study: NCT02771054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/FTC
Description: Change of nucleoside backbone
Study: NCT03585998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Concurrent radiotherapy Maintenance therapy
Study: NCT03129984

Intervention type: DEVICE
Intervention: Mandibular movement tracking
Description: Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
Study: NCT02345603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryo-therapy
Description: Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
Study: NCT04004325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4101
Description: FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4101
Description: FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4101 placebo
Description: FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4101 placebo
Description: FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterated Water
Description: Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterated Water
Description: Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
Study: NCT01280513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein intake
Description: 30% of energy intake coming from proteins
Study: NCT04547842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is given in arm D to prevent PONV
Study: NCT01476332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-urocanic acid 0,5% eye drops
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study: NCT01280513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein intake
Description: 9% of energy intake coming from proteins
Study: NCT02696161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose
Description: Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
Study: NCT01237067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
Study: NCT02394028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.
Study: NCT01237067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
Study: NCT01644994

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intracavitary cisplatin-fibrin
Description: single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
Study: NCT02394028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.
Study: NCT00984048

Intervention type: OTHER
Intervention: Needle core biopsies of liver metastasis
Description: No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
Study: NCT01476332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-urocanic acid 2.5% eye drops
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for cis-UCA, eye drops
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study: NCT02572245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PF-06410293 PFS
Description: PF-06410293 40 mg administered subcutaneously by Prefilled syringe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PF-06410293 PFP
Description: PF-06410293 40 mg administered subcutaneously by prefilled pen